HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ichinose, Y. Articles by Yagawa, K. Search for Related Content PubMed PubMed Citation Articles by Ichinose, Y. Articles by Yagawa, K.

The Journal of Thoracic and Cardiovascular Surgery, Vol 105, 1041-1046, Copyright © 1993 by The American Association for Thoracic Surgery and The Western Thoracic Surgical Association

ARTICLES

Hypotonic cisplatin treatment for carcinomatous pleuritis found at thoracotomy in patients with lung cancer. In vitro experiments and preliminary clinical results

Y Ichinose, N Hara, M Ohta, H Asoh, T Yano, K Maeda and K Yagawa
Department of Chest Surgery, National Kyushu Cancer Center, Fukuoka, Japan.

We have developed an intraoperative intrapleural treatment with the use of distilled water combined with cisplatin for carcinomatous pleuritis found at thoracotomy in patients with non-small-cell lung cancer. In the in vitro experiment, three different cell lines were used as a model of malignant pleural effusion. Cell growth was examined after a 3- day culture, which was preceded by exposure of the cells to cisplatin in either phosphate-buffered saline solution or distilled water for 1/2 to 5 minutes. The growth inhibition of tumor cells after hypotonic cisplatin treatment was significantly greater than after treatment with saline solution and cisplatin. Tumor that was obtained by resection of non-small-cell lung cancer was used as a model to demonstrate decreased viability of the tumor after exposure to hypotonic cisplatin. The viability of the tumor in a 6-day culture, preceded by exposure to hypotonic cisplatin (50 micrograms/ml) for 10 minutes, was markedly decreased. Intraoperative intrapleural hypotonic cisplatin was instilled in seven patients with pleural carcinomatosis without side effects and with control of pleural dissemination and pleural effusion for 6 to 29 months.

This article has been cited by other articles:

				N. Shigemura, A. Akashi, M. Ohta, and H. Matsuda Combined surgery of intrapleural perfusion hyperthermic chemotherapy and panpleuropneumonectomy for lung cancer with advanced pleural spread: a pilot study Interactive CardioVascular and Thoracic Surgery, December 1, 2003; 2(4): 671 - 675. [Abstract] [Full Text] [PDF]

				T. Osaki, K. Sugio, T. Hanagiri, M. Takenoyama, T. Yamashita, M. Sugaya, M. Yasuda, and K. Yasumoto Survival and prognostic factors of surgically resected T4 non-small cell lung cancer Ann. Thorac. Surg., June 1, 2003; 75(6): 1745 - 1751. [Abstract] [Full Text] [PDF]

				Y. Ichinose, R. Tsuchiya, T. Koike, T. Yasumitsu, K. Nakamura, H. Tada, H. Yoshimura, T. Mitsudomi, K. Nakagawa, K. Yokoi, et al. A prematurely terminated phase III trial of intraoperative intrapleural hypotonic cisplatin treatment in patients with resected non-small cell lung cancer with positive pleural lavage cytology: The incidence of carcinomatous pleuritis after surgical intervention J. Thorac. Cardiovasc. Surg., April 1, 2002; 123(4): 695 - 699. [Abstract] [Full Text] [PDF]

				Y. Ohta, Y. Tanaka, T. Hara, M. Oda, S.-i. Watanabe, J. Shimizu, and Y. Watanabe Clinicopathological and biological assessment of lung cancers with pleural dissemination Ann. Thorac. Surg., April 1, 2000; 69(4): 1025 - 1029. [Abstract] [Full Text] [PDF]